---
aliases: [GH, Guardant]
---
#actor #genomics #diagnostics #liquidbiopsy #usa #public

**Guardant Health** — Liquid biopsy pioneer. Shield first FDA-approved blood CRC test. Guardant360 tumor profiling.

---

## Why Guardant Health matters

| Metric | Value |
|--------|-------|
| Ticker | GH |
| Market cap | ~$4B |
| Founded | 2012 |
| Key product | **Shield** (first blood CRC screen) |
| HQ | Palo Alto, CA |

---

## Product portfolio

### Screening

| Product | Application | Status |
|---------|-------------|--------|
| **Shield** | CRC screening (blood) | **FDA approved** (Jul 2024) |
| Shield MCD | Multi-cancer detection | Breakthrough designation |

### Oncology

| Product | Application |
|---------|-------------|
| Guardant360 | Comprehensive tumor profiling |
| Guardant360 CDx | FDA-approved companion diagnostic |
| GuardantReveal | MRD monitoring |
| GuardantOmni | Research use |

---

## Shield CRC test

**First FDA-approved blood test for primary CRC screening**

| Milestone | Date |
|-----------|------|
| FDA approval | **Jul 2024** |
| NCCN guideline inclusion | 2025 |
| Medicare ADLT status | Apr 2025 |
| Medicare reimbursement | **$1,495** |

### Clinical performance

| Metric | Value |
|--------|-------|
| CRC sensitivity | **84%** |
| Specificity | **90%** |
| Stage I sensitivity | 62% |
| Stage II-IV sensitivity | 96-100% |
| Advanced adenoma | 13% |

### Recommended screening

- Every **3 years** (per NCCN)
- Ages 45+ (average risk)

---

## Guardant360

| Feature | Detail |
|---------|--------|
| Technology | Liquid biopsy (ctDNA) |
| Genes | 80+ cancer genes |
| Applications | Treatment selection, resistance |
| Status | FDA-approved CDx |

**Smart Liquid Biopsy (2025):** Nearly dozen new AI applications announced.

---

## Pipeline

| Program | Status |
|---------|--------|
| Shield MCD (multi-cancer) | FDA Breakthrough, NCI Vanguard |
| Colorectal MRD | Development |
| Breast screening | Early |

---

## Competitive landscape

| Segment | Competition |
|---------|-------------|
| CRC screening | [[Exact Sciences]] (Cologuard), Freenome |
| Multi-cancer | Grail (Galleri), [[Exact Sciences]] (Cancerguard) |
| Tumor profiling | Foundation Medicine, Tempus |
| MRD | [[Natera]] (Signatera) |

**Shield advantage:** Blood-based (easier than stool), first FDA approval.

**Shield limitation:** Lower adenoma detection than Cologuard.

---

## Investment case

**Bull:**
- First-mover in blood CRC screening
- $1,495 Medicare reimbursement secured
- NCCN guideline inclusion
- Shield MCD pipeline (multi-cancer)
- Guardant360 established oncology franchise

**Bear:**
- Shield sensitivity lower than colonoscopy
- Adenoma detection only 13%
- Competition from Exact Sciences, Grail
- Profitability still distant
- Natera leading in MRD

---

## Quick stats

| Metric | Value |
|--------|-------|
| Ticker | GH |
| Key product | Shield |
| Medicare rate | $1,495 |
| Focus | Liquid biopsy |

---

## Related

- [[Exact Sciences]] — competitor (Cologuard)
- [[Natera]] — competitor (MRD)
- [[Illumina]] — Grail competitor
- [[Tempus]] — competitor (oncology)
- [[Genomics]] — sector concept

---

## Sources

- [Shield FDA Approval](https://www.fda.gov/medical-devices/recently-approved-devices/shield-p230009)
- [Guardant ADLT Status](https://investors.guardanthealth.com/press-releases/press-releases/2025/Guardant-Health-Receives-ADLT-Status-From-CMS-for-Shield-Blood-Test/default.aspx)
- [NCCN Guidelines Update](https://investors.guardanthealth.com/press-releases/press-releases/2025/National-Comprehensive-Cancer-Network-NCCN-Updates-Colorectal-Cancer-Screening-Guidelines-to-Include-Shield-Blood-Based-Screening/default.aspx)

*Created 2026-01-09*
